Synthesis and Preclinical Evaluation of Radiolabeled [<sup>103</sup>Ru]BOLD-100

Synthesis and Preclinical Evaluation of Radiolabeled [<sup>103</sup>Ru]BOLD-100

The first-in-class ruthenium-based chemotherapeutic agent BOLD-100 (formerly IT-139, NKP-1339, KP1339) is currently the subject of clinical evaluation for the treatment of gastric, pancreatic, colorectal and bile duct cancer. A radiolabeled version of the compound could present a helpful diagnostic...

Full description

Bibliographic Details
Main Authors: Barbara Happl, Marie Brandt, Theresa Balber, Katarína Benčurová, Zeynep Talip, Alexander Voegele, Petra Heffeter, Wolfgang Kandioller, Nicholas P. Van der Meulen, Markus Mitterhauser, Marcus Hacker, Bernhard K. Keppler, Thomas L. Mindt
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Pharmaceutics
Subjects:
ruthenium-103
BOLD-100
anti-cancer metallodrugs
in vivo studies
pharmacokinetics
Online Access:https://www.mdpi.com/1999-4923/15/11/2626

Internet

https://www.mdpi.com/1999-4923/15/11/2626

Similar Items